Canaccord lowered the firm’s price target on Mind Medicine to $14 from $16 and keeps a Buy rating on the shares. The firm views the stock as signifcantly undervalued following its Q2 results and recent capital raise while noting catalysts are some time away.
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
Mind Medicine price target lowered to $14 from $16 at Canaccord
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1